Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with Reduced vs Standard Tacrolimus in Renal Transplant
NCT00170833Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2003
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Renal function as measured by serum creatinine at 6 months. Started Nov 2003; status: completed.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00170833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170833.